SANGAMO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4466 USD | -4.94% |
|
+6.03% | -17.80% |
Presenter SpeechLuca Issi (Analysts)[Audio Gap] Therapeutics for fireside chat as part of our ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
0.4466
USD
Average target price
3.5
USD
Spread / Average Target
+683.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.80% | 92.67M | |
| +16.45% | 122B | |
| +21.96% | 116B | |
| +23.73% | 27.03B | |
| -20.05% | 20.36B | |
| -16.28% | 15.91B | |
| -16.52% | 16.43B | |
| -44.35% | 15.6B | |
| +63.91% | 14.94B | |
| +2.52% | 13.59B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08
